---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-038576"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:45:09.016006+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics Q2 net loss $26M; cemsidomide MM ORR 40-50%; FDA align on Phase 2 dose by YE

## Summary
- Net loss of $26.0M ($0.37/share) on revenue $6.5M, down from $12.0M YoY.
- Cemsidomide Phase 1 MM data: ORR 40% at 75 µg and 50% at 100 µg; well-tolerated; highest dose 100 µg.
- Productive Type C meeting with FDA; registrational development expected to start early 2026; full data at IMS September 2025.
- Cash $223M as of June 30, 2025; runway extended to mid-2027.
- Preclinical milestone achieved under Merck KGaA collaboration; $1M earned.

## SEC filing metadata
- accession: 0001628280-25-038576
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828025038576/0001628280-25-038576-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828025038576/cccc-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-038576
- JSON: https://secwatch.observer/filing/0001628280-25-038576.json
- Plain text: https://secwatch.observer/filing/0001628280-25-038576.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.